MX2022010977A - Inhibidores de egfr, kras, braf y otros objetivos y uso de los mismos. - Google Patents

Inhibidores de egfr, kras, braf y otros objetivos y uso de los mismos.

Info

Publication number
MX2022010977A
MX2022010977A MX2022010977A MX2022010977A MX2022010977A MX 2022010977 A MX2022010977 A MX 2022010977A MX 2022010977 A MX2022010977 A MX 2022010977A MX 2022010977 A MX2022010977 A MX 2022010977A MX 2022010977 A MX2022010977 A MX 2022010977A
Authority
MX
Mexico
Prior art keywords
braf
kras
egfr
targets
inhibitors
Prior art date
Application number
MX2022010977A
Other languages
English (en)
Inventor
Alexander BRIDGES
Mukesh K Nyati
Jason Christopher Rech
Brennan Taylor Watch
Original Assignee
Univ Michigan Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan Regents filed Critical Univ Michigan Regents
Publication of MX2022010977A publication Critical patent/MX2022010977A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

En el presente documento se proporcionan compuestos que son útiles en el tratamiento del cáncer.
MX2022010977A 2020-03-05 2021-03-05 Inhibidores de egfr, kras, braf y otros objetivos y uso de los mismos. MX2022010977A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062985561P 2020-03-05 2020-03-05
PCT/US2021/020990 WO2021178741A1 (en) 2020-03-05 2021-03-05 Inhibitors of egfr, kras, braf, and other targets and use of the same

Publications (1)

Publication Number Publication Date
MX2022010977A true MX2022010977A (es) 2022-12-02

Family

ID=77612748

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010977A MX2022010977A (es) 2020-03-05 2021-03-05 Inhibidores de egfr, kras, braf y otros objetivos y uso de los mismos.

Country Status (11)

Country Link
US (1) US20230098205A1 (es)
EP (1) EP4114386A1 (es)
JP (1) JP2023515689A (es)
KR (1) KR20220150358A (es)
CN (1) CN115768423A (es)
AU (1) AU2021230553A1 (es)
BR (1) BR112022017724A2 (es)
CA (1) CA3174538A1 (es)
IL (1) IL296091A (es)
MX (1) MX2022010977A (es)
WO (1) WO2021178741A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11932633B2 (en) 2018-05-07 2024-03-19 Mirati Therapeutics, Inc. KRas G12C inhibitors
EP3908283A4 (en) 2019-01-10 2022-10-12 Mirati Therapeutics, Inc. KRAS G12C INHIBITORS
US11453683B1 (en) 2019-08-29 2022-09-27 Mirati Therapeutics, Inc. KRas G12D inhibitors
MX2022003537A (es) 2019-09-24 2022-07-11 Mirati Therapeutics Inc Terapias de combinacion.
KR20220130126A (ko) 2019-12-20 2022-09-26 미라티 테라퓨틱스, 인크. Sos1 억제제

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3547977A (en) * 1967-10-27 1970-12-15 Velsicol Chemical Corp Novel carbanilates

Also Published As

Publication number Publication date
US20230098205A1 (en) 2023-03-30
CN115768423A (zh) 2023-03-07
JP2023515689A (ja) 2023-04-13
IL296091A (en) 2022-11-01
WO2021178741A1 (en) 2021-09-10
CA3174538A1 (en) 2021-09-10
AU2021230553A1 (en) 2022-10-13
EP4114386A1 (en) 2023-01-11
KR20220150358A (ko) 2022-11-10
BR112022017724A2 (pt) 2022-10-18

Similar Documents

Publication Publication Date Title
MX2022010975A (es) Inhibidores de egfr, kras, braf y otras dianas y uso de estos.
MX2022010977A (es) Inhibidores de egfr, kras, braf y otros objetivos y uso de los mismos.
MX2020012261A (es) Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer.
PH12021500004A1 (en) Pd-1/pd-l1 inhibitors
MX2022004656A (es) Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer.
PH12020551244A1 (en) Pd-1/pd-l1 inhibitors
MX2020012204A (es) Inhibidores de kras g12c para tratar el cáncer.
ZA202202559B (en) Kras g12c inhibitors and methods of using the same
MX2020012731A (es) Inhibidores de kras g12c y metodos para su uso.
MX2020010836A (es) Inhibidores de kras g12c y métodos para su uso.
MX2021005700A (es) Inhibidores de kras g12c y metodos de uso de los mismos.
MX2020011582A (es) Inhibidores de kras g12c y metodos para su uso.
MX2020011907A (es) Inhibidores de kras g12c para el tratamiento de cancer.
MX2020002502A (es) Inhibidores de kras g12c y metodos para utilizarlos.
MX2019008701A (es) Terapia de combinacion que involucra compuestos macrociclicos de diarilo.
MX2021007773A (es) Compuestos inhibidores de egfr.
MX2023005747A (es) Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos.
MX2020011684A (es) Inhibicion combinada de pd-1/pd-l1, tgfbeta y dna-pk para el tratamiento del cancer.
MX2021008834A (es) Metodos de tratamiento del cancer de mama con tucatinib.
MX2022006500A (es) Terapia de combinacion que involucra compuestos macrociclicos de diarilo.
WO2018081817A3 (en) Targeting microrna-101-3p in cancer therapy
MX2021010603A (es) Inhibidores de caspasa y metodos de uso de los mismos.
WO2020014583A8 (en) Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a method of treating a cancer or a solid tumor
MX2023002104A (es) Composiciones y métodos para tratar cánceres positivos para egfr.
WO2019070777A3 (en) Pim kinase inhibitors in combination with autophagy inhibitors for treatment of cancers